Stockscreener 앱 받기
25.16
1.68%
-0.43
시간 외 거래:
24.90
-0.26
-1.03%
전일 마감가:
$25.59
열려 있는:
$26
하루 거래량:
1.66M
Relative Volume:
0.92
시가총액:
$2.56B
수익:
$139.74M
순이익/손실:
$-79.99M
주가수익비율:
-24.77
EPS:
-1.0157
순현금흐름:
$-360.05M
1주 성능:
-5.20%
1개월 성능:
-9.89%
6개월 성능:
+22.14%
1년 성능:
+0.40%
1일 변동 폭
$24.75
$26.23
1주일 범위
$24.60
$27.92
52주 변동 폭
$13.53
$36.44
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
25.16 | 2.56B | 139.74M | -79.99M | -360.05M | -1.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
Beam Therapeutics Inc. $BEAM is Casdin Capital LLC's 9th Largest Position - MarketBeat
Integral Health Asset Management LLC Decreases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - Yahoo Finance
H.C. Wainwright Keeps Their Buy Rating on Beam Therapeutics (BEAM) - The Globe and Mail
BEAM.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Liquidity Mapping Around (BEAM) Price Events - Stock Traders Daily
According to a document submitted to the U.S. Securities and Exchange Commission (SEC) on March 2, Beam Therapeutics Inc. and Bio Palette have jointly decided to terminate the licensing agreement signed by both parties on March 27, 2019. - Bitget
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit - TipRanks
Beam Therapeutics Inc. Terminates License Agreement with Bio Palette Co., Ltd - marketscreener.com
HC Wainwright Predicts Weaker Earnings for Beam Therapeutics - MarketBeat
JPMorgan Chase & Co. Trims Stock Position in Beam Therapeutics Inc. $BEAM - MarketBeat
ARK Investment Boosts Stake in Beam Therapeutics - National Today
Amova Asset Management Americas Inc. Buys 103,939 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
ARK Investment Management LLC Increases Position in Beam Therapeutics Inc. $BEAM - MarketBeat
Beam Therapeutics Earnings Call Highlights PKU Pivot - TipRanks
What is HC Wainwright's Forecast for BEAM Q1 Earnings? - MarketBeat
Mintz Advises Sixth Street On $500 Million Strategic Financing Facility With Beam Therapeutics - Mondaq
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - mx.advfn.com
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com
Contrarius Group Holdings Ltd Buys Shares of 1,533,269 Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vanguard Group Inc. Sells 455,440 Shares of Beam Therapeutics Inc. $BEAM - MarketBeat
BEAM SEC FilingsBeam Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Beam Therapeutics (NASDAQ:BEAM) Raised to Hold at Wall Street Zen - MarketBeat
BEAM.O PE Ratio & Valuation, Is BEAM.O Overvalued - Intellectia AI
RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here’s Why - Yahoo Finance
BEAM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Should You Buy Beam Therapeutics Inc (BEAM) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Assessing Beam Therapeutics (BEAM) Valuation After Q4 Earnings Surprise Credit Facility And PKU Program Launch - simplywall.st
RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here's Why - Bitget
Beam Therapeutics: Great Potential, But Patience Is Needed (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics reveals new program for PKU - BioWorld MedTech
Bernstein SocGen cuts Beam Therapeutics stock price target on valuation By Investing.com - Investing.com Canada
Bernstein SocGen cuts Beam Therapeutics stock price target on valuation - Investing.com
Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing - Yahoo Finance
Beam Therapeutics (BEAM) Quarterly Profit Surprises Loss Narrative With US$244.3 Million Net Income - simplywall.st
Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.3%Time to Sell? - MarketBeat
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street - WilmerHale
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y - Finviz
Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $26.00 - MarketBeat
BEAM Shares See Target Price Boost by RBC Capital | BEAM Stock N - GuruFocus
Beam Therapeutics Stock Surges 14% on Strategic Financing: How the $500M Agreement Secures a $156 Target - TIKR.com
Beam Therapeutics Opens with 7.83% Gain, Outperforming S&P 500's 0.69% Rise - Markets Mojo
Beam Therapeutics Hits Day High with 17.04% Surge in Stock Price - Markets Mojo
Wedbush Raises BEAM Price Target to $65, Maintains Outperform Ra - GuruFocus
Beam Therapeutics (NASDAQ:BEAM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Beam Therapeutics (BEAM) stock edges up premarket after 14% jump on results, $500 million facility - Bez Kabli
RBC Capital Adjusts Beam Therapeutics Price Target to $26 From $22, Maintains Sector PerformSpeculative Risk Rating - marketscreener.com
Beam Therapeutics Inc. (NASDAQ:BEAM) Q4 2025 Earnings Call Transcript - Insider Monkey
Mintz Advises Sixth Street on $500 Million Strategic Financing Facility with Beam Therapeutics - Mintz
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
1.21%
자본화:
|
볼륨(24시간):